Case Report

Fludrocortisone Therapy for Hypercalcemia

Authors: GALEN L. BARBOUR, MD

Abstract

HYPERCALCEMIA of varying severity is common in patients with malignancy. Patients with mild hypercalcemia may develop anorexia or vomiting, subsequent dehydration and worsened hypercalcemia, potentially to lethal levels. Long-term management of these patients should include an attempt to lower the serum calcium and reduce this risk. The purpose of this report is to document the efficacy of the synthetic mineralocorticoid, 9a-fludrocortisone, in lowering the serum calcium in a patient with hypercalcemia caused by lung cancer.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References